Kappa‐opioid receptor agonists increase locomotor activity in the monoamine‐depleted rat model of parkinsonism

Movement Disorders - Tập 13 Số 2 - Trang 228-233 - 1998
Neill Hughes1, A.T. McKnight2, G.N. Woodruff2, Michael P. Hill1, Alan R. Crossman1, Jonathan M. Brotchie1
1Division of Neuroscience, School of Biological Sciences, University of Manchester, Manchester, U.K.
2Parke-Davis Neuroscience Research Centre, Cambridge University, Cambridge, U.K.

Tóm tắt

AbstractExcessive glutamate transmission in the basal ganglia is a major factor in the neural mechanisms underlying parkinsonian akinesia. Activation of K opioid receptors causes a presynaptic reduction in glutamate release. K opioid receptors are concentrated in those regions of the basal ganglia associated with increased glutamate transmission in parkinsonism. In this study, we use the α‐methyl‐p‐tyrosine and reserpine‐treated rat model of parkinsonism to investigate whether systemic administration of the K opioid agonists enadoline (CI‐977) and U69,593 can alleviate the symptoms of parkinsonism either alone or in conjunction with dopamine replacement therapy. We report that, when administered alone, both enadoline and U69,593 can increase locomotion in monoamine‐depleted rats. No increase in locomotor activity was seen after K opioid agonist administration in non‐parkinsonian rats. The responses to K opioid agonists were blocked by co‐administration of either the nonspecific opioid receptor antagonist naloxone or the selective K opioid receptor antagonist nor‐binaltorphimine (nor‐BNI). An important finding is that when enadoline and L‐dopa administered togethe, their anti‐akinetic properties are synergistic. Thus, the doses of enadoline and L‐dopa required to alleviate akinesia when administered together are lower than either administered alone. These data illustrate the importance of K opioid receptors in the neural mechanisms controlling voluntary movement and suggest that K opioid agonists may have a role as adjuncts to dopamine replacement in the management of Parkinson's disease.

Từ khóa


Tài liệu tham khảo

10.1016/0306-4522(89)90120-6

10.1007/978-1-4684-5347-8_29

10.1002/mds.870060208

10.1016/0006-8993(79)90884-9

10.1016/0014-4886(91)90173-A

10.1002/ana.410340413

10.1002/ana.410280411

10.1002/ana.410300513

Locke KW, 1986, Behavioral effects of opioid peptides selective for μ and δ receptors. II. Locomotor activity in nondependent and morphine‐dependent rats, J Pharmacol Exp Ther, 238, 997

10.1007/BF02244249

10.1007/BF00216060

10.1007/BF00176854

10.1073/pnas.79.18.5703

10.1111/j.1476-5381.1991.tb12203.x

10.1016/S0006-8993(10)80029-0

10.1016/0306-4522(92)90123-J

10.1016/0306-4522(87)90015-7

10.1038/362423a0

10.1016/0006-8993(95)00358-W

10.1016/0014-2999(95)00385-X

Boyle SJ, 1990, [3H]‐CI‐977: a highly selective ligand for the k‐opioid receptor in both guinea pig and rat forebrain, Molecular Neuropharmacology, 1, 23

10.1073/pnas.85.11.4061

10.1016/0024-3205(90)90346-S

10.1007/BF00184286

Rech RH, 1968, Behavioral effects of α‐methyltyrosine after prior depletion of brain catecholamines, J Pharmacol Exp Ther, 160, 326

10.1111/j.1476-5381.1990.tb12110.x

10.1016/0014-2999(85)90431-5

10.1016/0024-3205(87)90585-6

10.1038/1801200a0

Quinn GP, 1959, Biochemical and pharmacological studies of RO 1‐9569 (tetrabenazine), a non‐indole tranquilizing agent with reserpine‐like effects, J Pharmacol Exp Ther, 127, 103

Manzanares J, 1991, Kappa opioid receptormediated regulation of dopaminergic neurons in the rat brain, J Pharmacol Exp Ther, 256, 500

10.1097/00008877-199508000-00010

10.1097/00002826-199310000-00007

10.1016/0014-2999(91)90682-G

10.1126/science.3016896

Iwamoto ET., 1981, Locomotor activity and antinociception after putative μ, k and σ opioid receptor agonists in the rat: influence of dopaminergic agonists and antagonists, J Pharmacol Exp Ther, 217, 451

Thông tin
Thông tin xuất bản

Movement Disorders

Tập 13 Số 2

228-233

Thông tin tác giả